This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Toxic Stocks That May Not Let You Prosper
by Rimmi Singhi
If you own toxic stocks for long, you are likely to see a big loss in your wealth. Stay away from toxic stocks like BALY, OMCL, AY and TFSL.
Earnings Preview: Omnicell (OMCL) Q4 Earnings Expected to Decline
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 4 Toxic Stocks May Bring Bad Luck to Your Portfolio
by Rimmi Singhi
Consider dumping toxic stocks like BALY, OMCL, ILMN and AY from your portfolio to avoid huge losses.
Do Options Traders Know Something About Omnicell (OMCL) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Omnicell (OMCL) stock based on the movements in the options market lately.
5 Toxic Stocks That Can Set Off Alarm Bells for Your Portfolio
by Rimmi Singhi
Investors who can correctly spot overpriced stocks and shun them at the right time can avoid big losses. Dump toxic stocks like MGM, ILMN, OMCL, HL and RDNT to prevent portfolio bleeding.
Omnicell (OMCL) Ailed by Mounting Costs, Macroeconomic Issues
by Zacks Equity Research
Macroeconomic factors adversely affect bookings and revenues in Omnicell's (OMCL) point-of-care business. The company reduces its overall bookings and revenue outlook for the year.
Omnicell (OMCL) Q3 Earnings Beat Estimates, Guidance Cut
by Zacks Equity Research
Rise in operating expenses result in an operating loss in Q3 for Omnicell (OMCL), placing significant pressure on the bottom line.
Omnicell (OMCL) Q3 Earnings Top Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 6.38% and 4.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MDRX vs. OMCL: Which Stock Is the Better Value Option?
by Zacks Equity Research
MDRX vs. OMCL: Which Stock Is the Better Value Option?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJT
Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLYG
Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down
by Zacks Equity Research
Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.
MDRX vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MDRX vs. OMCL: Which Stock Is the Better Value Option?
Omnicell (OMCL) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of -1.18% and 2.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLY
Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Reasons to Add Patterson Companies (PDCO) to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJT
Quest Diagnostics' (DGX) Base Business Grows Despite Margin Woes
by Zacks Equity Research
Quest Diagnostics (DGX) continues to make inroads with its health plans, gaining share and increasing revenues faster than the market.
BD's (BDX) New Combination Test to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) latest combination test is expected to speed up the detection of the infection-causing viruses, thereby accelerating the implementation of the appropriate treatment plan.
Catalent (CTLT) Expands Packaging Capabilities at Japan Facility
by Zacks Equity Research
Catalent's (CTLT) latest capability expansion is expected to boost its business in this key hub in its Asia-Pacific Clinical Supply Services network.